New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:02 EDTISIS, BIIBIsis receives $14M payment from Biogen with Phase 1 initiation
Isis Pharmaceuticals (ISIS) announced that it has initiated a Phase 1 study for ISIS-DMPK. Isis earned a $14M milestone payment from Biogen Idec (BIIB) associated with this achievement. ISIS-DMPK is designed to reduce the production of toxic dystrophia myotonica-protein kinase RNA in cells, including muscle cells, for the treatment of Myotonic Dystrophy Type.
News For ISIS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
11:08 EDTBIIBBiogen to add PML info on Tecfidera label after patient dies
Subscribe for More Information
11:04 EDTBIIBFDA says Biogen adding PML information on Tecfidera label
07:09 EDTISISIsis Pharmaceuticals initiates pivotal Phase 3 study evaluating ISIS-SMN
Subscribe for More Information
November 24, 2014
07:59 EDTBIIBBiogen resumed with an Outperform at Leerink
Subscribe for More Information
November 20, 2014
07:24 EDTISISGoldman to hold a conference
Subscribe for More Information
06:40 EDTISISIsis Pharmaceuticals price target raised to $62 from $53 at Piper Jaffray
Subscribe for More Information
November 19, 2014
07:52 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
07:21 EDTBIIBBiogen price target lowered to $400 from $425 at Credit Suisse
Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.
November 18, 2014
15:48 EDTISISGenzyme, Isis present KYNAMRO data at AHA meeting
Genzyme, a Sanofi (SNY) company, and Isis Pharmaceuticals (ISIS) announced that new two-year data from a phase 3 long-term extension study of KYNAMRO injection was presented at a scientific session at the annual American Heart Association meeting. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events compared to two years prior to therapy. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO. In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO.
November 14, 2014
15:41 EDTISISIsis Pharmaceuticals management to meet with Piper Jaffray
Meeting to be held in Kansas City, MO on November 18 hosted by Piper Jaffray.
November 13, 2014
10:42 EDTBIIBSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
05:34 EDTISISAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information
November 12, 2014
08:13 EDTBIIBBoston Biotech to hold a conference
Subscribe for More Information
07:53 EDTISISLeerink to hold a tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use